The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
Arecor Ltd, the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce the European Patent Office (“EPO”) has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies such as trastuzumab or ustekinumab or fusion proteins such as abatacept.
“Arecor’s proprietary insulin product to progress into human clinical trials in 2018”
Arecor and its partner, non-profit company, Global Alliance for Livestock Veterinary Medicines (GALVmed), have successfully stabilised liquid formulations of vaccines to combat two major diseases of livestock across the developing world including Africa, Asia and the Middle East
In this work, the ArestatTM technology has been applied to enable a vaccine to be distributed pre-prepared in a liquid format without the requirement for in-field reconstitution from the freeze-dried powder form
ArestatTM technology has also been applied to reduce the cost of a batch of vaccine diluent by 96 per cent., thereby improving its distribution and uptake by farmers
Arecor’s formulation technology work has been supported by Innovate UK through UK aid of the UK government and the Bill & Melinda Gates Foundation
Cambridge, UK., 8th December 2017: Arecor Ltd (“the Company”), a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology ...
Notification of an ‘intention to grant’ patent protecting Arecor’s novel approach to enabling stable liquid adenovirus formulations, has been received from both the European and US patent offices.
“The Company features alongside The Prime Minister, The Rt Hon Theresa May MP, and a small number of outstanding organisations in the Technology edition”
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.